Martinus Adrianus van Osch
Fondatore presso Forbion Capital Partners Management Holding BV
Provenienza dei contatti di primo grado di Martinus Adrianus van Osch
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.
41
| Private Company | Investment Managers | 41 |
FlowMedica, Inc.
 FlowMedica, Inc. Medical SpecialtiesHealth Technology FlowMedica, Inc. develops intravascular systems and medical devices. The company's products include Benephit CV, PVSolo, PVMini, and XT Infusion systems. It also develops novel, proprietary, and minimally invasive intravascular systems for implementing Targeted Renal Therapy. The company was founded in 2002 and is headquartered in Fremont, CA.
9
| Subsidiary | Medical Specialties | 9 |
Mitralign, Inc.
 Mitralign, Inc. Medical SpecialtiesHealth Technology Mitralign, Inc. operates as a valve repair company that engages in transcatheter annuloplasty system designed to treat both functional tricuspid regurgitation and mitral regurgitation. The Mitralign Percutaneous Annuloplasty System, MPAS, is intended for the treatment of symptomatic functional mitral regurgitation for annular reduction through tissue plication. The company was founded by Paul A. Spence and Richard P. Geoffrion in 2003 and is headquartered in Tewksbury, MA.
9
| Subsidiary | Medical Specialties | 9 |
Autonomic Technologies, Inc.
 Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA.
7
| Subsidiary | Electronic Equipment/Instruments | 7 |
X-Cell Medical, Inc.
 X-Cell Medical, Inc. Medical SpecialtiesHealth Technology X-Cell Medical, Inc. develops drugs for cardiovascular clinical applications. It focuses on delivery of drugs with safety and efficacy profiles for cardiovascular indications including restenosis, myocardial infarction and vulnerable plaque. The company was founded in 2002 and is headquartered in Monmouth Junction, NJ.
6
| Private Company | Medical Specialties | 6 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Martinus Adrianus van Osch tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
NewAmsterdam Pharma BV
 NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Founder Chairman Chief Tech/Sci/R&D Officer Director/Board Member Chief Operating Officer Director/Board Member | |
VectorY BV
 VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chief Executive Officer Director/Board Member Director/Board Member Chairman Corporate Officer/Principal | |
| University of Groningen | College/University | Graduate Degree Graduate Degree Doctorate Degree Doctorate Degree Graduate Degree | |
| University of Amsterdam | College/University | Masters Business Admin Doctorate Degree Undergraduate Degree Corporate Officer/Principal | |
Oxitope Pharma BV
 Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director/Board Member Director/Board Member | |
| UNIQURE N.V. | Biotechnology | Chairman Founder Director/Board Member | |
| Stanford University | College/University | Graduate Degree Masters Business Admin Undergraduate Degree | |
Complement Therapeutics Ltd.
 Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners is an Independent Venture Capital firm founded in 1992 by Edmund Martin Olivier, Alan G. Walton and Cornelius T. Ryan. The firm is headquartered in Boston. | Investment Managers | Private Equity Investor Private Equity Investor Private Equity Investor | |
Academic Medical Center
 Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
Inversago Pharma, Inc.
 Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member Founder Director/Board Member | |
Xention Pharma Ltd.
 Xention Pharma Ltd. Pharmaceuticals: MajorHealth Technology Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer Founder | |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member Director/Board Member | |
| University of Utrecht | College/University | Corporate Officer/Principal Doctorate Degree Graduate Degree | |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Chairman Director/Board Member Founder | |
enGene, Inc.
 enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member Director/Board Member | |
| University of California San Diego | College/University | Undergraduate Degree Corporate Officer/Principal | |
Staten Biotechnology BV
 Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
Numab Therapeutics AG
 Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd | Investment Managers | Private Equity Investor Private Equity Investor | |
Metrion Biosciences Ltd.
 Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Biotechnology | Director/Board Member Director/Board Member | |
Mestag Therapeutics Ltd.
 Mestag Therapeutics Ltd. Financial ConglomeratesFinance Mestag Therapeutics Ltd. is engaged in the biotechnology industry. The company was founded on February 17, 2020 and is headquartered in Cambridge, the United Kingdom. | Financial Conglomerates | Chairman Director/Board Member | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Chairman Director/Board Member | |
Pulmagen Therapeutics (Synergy) Ltd.
 Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Director/Board Member | |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Biotechnology | Chairman Director/Board Member | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark. | Investment Managers | Corporate Officer/Principal Private Equity Analyst | |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel. | College/University | Doctorate Degree Masters Business Admin | |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal Director/Board Member | |
| ENGENE HOLDINGS INC. | Biotechnology | Director/Board Member Director/Board Member | |
Exosome Diagnostics, Inc.
 Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
Amakem NV
 Amakem NV Medical/Nursing ServicesHealth Services Amakem NV operates as a biopharmaceutical company. It uses kinase inhibitors for treatments of bowel, eye, and lung diseases. The company was founded by Jack Elands, Dirk Leysen, Olivier Raynald Defert, and Nadya Kaval on July 22, 2009 and is headquartered in Diepenbeek, Belgium. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
BioVex Group, Inc.
 BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Biotechnology | Chief Executive Officer Director/Board Member | |
| University of Cambridge | College/University | Corporate Officer/Principal Masters Business Admin | |
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| REPLIMUNE GROUP, INC. | Biotechnology | Founder Director/Board Member | |
| OBSEVA SA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| Oxyrane, Ltd. | Chairman Director/Board Member | ||
Coherex Medical, Inc.
 Coherex Medical, Inc. Medical SpecialtiesHealth Technology Coherex Medical, Inc. designs, develops, and markets catheter-based technologies for the treatment of structural heart defects. It offers WaveCrest device that is placed in the opening of the left atrial appendage to reduce complications associated with other device types, as well as simplifies the implant procedures. The company was founded by Brian K. Whisenant and Clark C. Davis in 2003 and is headquartered in Salt Lake City, UT. | Medical Specialties | Director/Board Member Director/Board Member | |
| DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 15 |
| Paesi Bassi | 14 |
| Regno Unito | 10 |
| Svizzera | 5 |
| Canada | 4 |
Settori
| Health Technology | 29 |
| Consumer Services | 8 |
| Finance | 7 |
| Commercial Services | 6 |
| Health Services | 4 |
Posizioni
| Director/Board Member | 361 |
| Corporate Officer/Principal | 135 |
| Private Equity Investor | 62 |
| Chairman | 55 |
| Founder | 54 |
Contatti più connessi
| Insiders | |
|---|---|
| Dana Mead | 40 |
| Hugo Slootweg | 34 |
| Patrick Volkert Vink | 30 |
| Dan Cole | 30 |
| Nanna Liebach Lüneborg | 29 |
| Michael Hayden | 27 |
| Peter Andersen | 26 |
| Omar Amirana | 23 |
| Steve D. Weinstein | 23 |
| David Mauney | 22 |
| Yuval Binur | 21 |
| Reza Zadno | 20 |
| Alexander G. Asam | 18 |
| Geert-Jan Mulder | 17 |
| Sander J. van Deventer | 17 |
- Borsa valori
- Insiders
- Martinus Adrianus van Osch
- Connessioni Società
